TheraRadar
Data updated: May 26, 2026

MERILOG SOLOSTAR (insulin aspart-szjj)

Metabolic Approved 2025-02-14

MERILOG (insulin aspart-szjj) is a rapid-acting human insulin analog. It is indicated to improve glycemic control in both adult and pediatric patients with diabetes mellitus. The medication serves as a therapeutic tool for managing blood sugar levels in patients requiring insulin replacement or supplementation.

Source: FDA Label • SANOFI-AVENTIS U.S. LLC • Insulin Analog

How MERILOG SOLOSTAR Works

MERILOG regulates glucose metabolism by lowering blood glucose levels through multiple pathways. It stimulates peripheral glucose uptake, specifically in skeletal muscle and fat, and inhibits the liver's production of glucose. Additionally, the drug prevents the breakdown of fats and proteins while promoting protein synthesis.

1
Indication
--
Phase 3 Trials
1
Years on Market

Details

Status
Prescription
First Approved
2025-02-14
Routes
SOLUTION
Dosage Forms
INJECTION

Companies

Active Ingredient: INSULIN ASPART-SZJJ

MERILOG SOLOSTAR Approval History

2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2025 to 2025
Feb 2025 ORIGINAL
Update

What MERILOG SOLOSTAR Treats

1 indications

MERILOG SOLOSTAR is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Diabetes
Source: FDA Label
Biosimilar for Fiasp

MERILOG SOLOSTAR is a lower-cost alternative to Fiasp with no clinically meaningful differences. Requires prescriber approval to substitute.

MERILOG SOLOSTAR Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 18 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

What's emerging in MERILOG SOLOSTAR's indications

See all emerging drugs →

Phase 3 candidates targeting molecules with no FDA-approved drug, in indications MERILOG SOLOSTAR treats. First-in-class if their pivotal trials read out positive.

Drugs Similar to MERILOG SOLOSTAR

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADMELOG
INSULIN LISPRO
1 shared
SANOFI-AVENTIS US
Shared indications:
ADMELOG SOLOSTAR
INSULIN LISPRO
1 shared
SANOFI-AVENTIS US
Shared indications:
AFREZZA
INSULIN RECOMBINANT HUMAN
1 shared
MANNKIND
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MERILOG SOLOSTAR FDA Label Details

Indications & Usage

FDA Label (PDF)

MERILOG SOLOSTAR is indicated for the treatment of Diabetes.

Track MERILOG SOLOSTAR with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.